PIA Publications
Biofluid Based Biomarkers

Articles of Interest

January 2017

O'Bryant, S., Mielke, M., Rissman, R., Lista, S., Vanderstichele, H., & Zetterberg, H. et al. (2017). Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's & Dementia, 13(1), 45-58.

Dage, J., Airey, D., Wennberg, A., Hagen, C., Knopman, D., & Machulda, M. et al. (2016). Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimer's & Dementia, 12(7), P877-P878.

Gispert, J., Suárez-Calvet, M., Monté, G., Tucholka, A., Falcon, C., & Rojas, S. et al. (2016). Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's & Dementia, 12(12), 1259-1272. 

Mehta, K. & Yeo, G. (2017). Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimer's & Dementia, 13(1), 72-83.  

Iulita, M., Ower, A., Barone, C., Pentz, R., Gubert, P., & Romano, C. et al. (2016). An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimer's & Dementia, 12(11), 1132-1148.  

Bereczki, E., Francis, P., Howlett, D., Pereira, J., Höglund, K., & Bogstedt, A. et al. (2016). Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. Alzheimer's & Dementia, 12(11), 1149-1158. 

September 2015

Donohue, M., Moghadam, S., Roe, A., Sun, C., Edland, S., & Thomas, R. et al. (2015). Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimer's & Dementia, 11(9), 1069-1079. 

Lehmann, S., Gabelle, A., & Paquet, C. (2015). Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis? Alzheimer's & Dementia, 11(9), 1125-1126.